Under a limited option-to-license agreement from Yeda, Prolor has been developing oxyntomodulin peptide, a drug compound using this technology as a treatment of obesity and has now exercised its option to license the technology.
Prolor chairman Phillip Frost said this license from the prestigious Weizmann Institute of Science represents an exciting opportunity for Prolor.
"It complements our core platform and expands our pipeline of competitive therapeutic drug candidates to include new, important clinical indications," Frost said.